drugset / Trial / NCT05047484
A Study of Multiple Doses of ALXN2050 in Healthy Adults
Phase 1
Completed
45 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This was a Phase 1, placebo-controlled, randomized, double-blind (participant and investigator blind, sponsor open), multiple-ascending dose study conducted in healthy participants to demonstrate the safety and tolerability and to evaluate the pharmacokinetics and pharmacodynamics of ACH-0145228 (ALXN2050).
Timeline
- Start
- 2019-01-07
- Primary completion
- 2019-07-23
- Completion
- 2019-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vemircopan | Small molecule | 40 mg | — |
| Subject | Vemircopan | Small molecule | 80 mg | — |
| Subject | Vemircopan | Small molecule | 120 mg | — |
| Subject | Vemircopan | Small molecule | 200 mg | — |
| Subject | Vemircopan | Small molecule | 240 mg | — |
Indications
No indication recorded.